statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Head of Institutional Equities at HDFC Securities expects consumption demand to witness a slight pickup in FY25 and suggests adding exposure to the FMCG sector on a selective basis.

Daily Voice | These 4 pharma stocks to benefit from change in 2 trends: HDFC Securities' Unmesh Sharma

As long as the Nifty 50 holds 22,300-22,200 levels on closing basis, the upward march towards 22,800 can't be ruled out in the coming sessions.

Top 10 stock ideas for May series when D-St bulls charge Nifty towards 22,800

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Steady US sales to bring a healthy quarter for pharma sector

Aurobindo Pharma share price | The share touched a 52-week high of Rs 1,177.00 and a 52-week low of Rs 517.55 on 30 January, 2024 and 05 April, 2023, respectively.

Aurobindo Pharma falls after US FDA issues 3 observations on Andhra arm

Penicillin-G (Pen-G) facility, located in a SEZ at Kakinada in Andhra Pradesh, has a production capacity of 15,000 tonne per annum and also 1.8 lakh tonne of gulcose, while 6-Amino Penicillanic Acid plant has a capacity to produce 3,600 tonne annually, the drug maker said in a press release.

Aurobindo Pharma commissions four plants in Andhra Pradesh including Pen-G facility

In terms of levels, immediate resistance is identified at 22,530, a level of significant importance on higher time frames, with further resistance seen at 22,800 followed by 23,170 for the Nifty.

Short-term picks: Three stocks that may generate 17-25% returns in next 2-3 weeks

The share touched a 52-week high of Rs 1,177 on January 30, 2024 and a 52-week low of Rs 466 on March 21, 2023.

Aurobindo Pharma share up nearly 2% on USFDA approval for nasal spray

Aurobindo Pharma subsidiary's Telangana plant was slapped with 7 observations by the US FDA after its inspection of the unit from February 19-29.

Aurobindo Pharma trades 2% down as US FDA spots issues in Telangana unit

The share touched a 52-week high of Rs 1,177.00 and a 52-week low of Rs 443.15 on 30 January, 2024 and 14 March, 2023, respectively.

Aurobindo Pharma restarts aseptic product distribution; shares trade higher

The Prequalification Unit Inspection Team (PQT-INS) of World Health organization (WHO) had conducted an inspection at the Unit IV from September 11 to September 15, 2023.

Aurobindo Pharma arm gets WHO GMP approval; shares flat

Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. It operates under the following geographical segments: India, USA, Europe, and Rest of the World. Its portfolio includes antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterological, anti-allergies, and anti-diabetics. The company was founded by Penaka Venkata Ramprasad Reddy and Kambam Nithyananda Reddy on December 26, 1986 and is headquartered in Hyderabad, India.

52-Wk High	1,177.10
52-Wk Low	581.25

Current Price	0.00
Prev Close	1,147.00
Open	0.00
Dividend Yield	0.58%
50-Day Moving Average	1,076.64
Beta	-0.02
Avg. Volume	1.73M
PE Ratio	24.36

52-Week High	1,177.10
52-Week Low	581.25
Market Capitalization	674.8B
EPS	47.28
Price to Book	2.39
Revenue Per Employee	8.35M
Enterprise Value/EBITDA	10.29

AUROPHARMA.NSE Aurobindo Pharma Ltd.

About

Feed

News

Sentiment

Fundamentals